Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 4
1998 6
1999 2
2000 6
2001 2
2002 1
2003 1
2004 1
2005 1
2006 1
2007 3
2008 2
2009 3
2010 3
2011 2
2012 2
2013 4
2014 3
2015 3
2016 3
2017 6
2018 4
2019 1
2020 7
2021 8
2022 2
2023 2
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Rambaldi A, et al. Among authors: mordini n. Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28. Lancet Oncol. 2015. PMID: 26429297 Free article. Clinical Trial.
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
Cavallaro G, Grassi A, Pavoni C, Micò MC, Busca A, Cavattoni IM, Santarone S, Borghero C, Olivieri A, Milone G, Chiusolo P, Musto P, Saccardi R, Patriarca F, Pane F, Saporiti G, Rivela P, Terruzzi E, Cerretti R, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Bernasconi P, Iori AP, Castagna L, Mordini N, Oldani E, Di Grazia C, Bacigalupo A, Rambaldi A. Cavallaro G, et al. Among authors: mordini n. Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5. Blood Cancer J. 2024. PMID: 39168989 Free PMC article. Clinical Trial.
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Kröger N, et al. Among authors: mordini n. N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002. N Engl J Med. 2016. PMID: 26735993 Free article. Clinical Trial.
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.
Rovó A, Gras L, Piepenbroek B, Kröger N, Reinhardt HC, Radujkovic A, Blaise D, Kobbe G, Niityvuopio R, Platzbecker U, Sockel K, Hunault-Berger M, Cornelissen JJ, Forcade E, Bourhis JH, Chalandon Y, Kinsella F, Nguyen-Quoc S, Maertens J, Elmaagacli A, Mordini N, Hayden P, Raj K, Drozd-Sokolowska J, de Wreede LC, McLornan DP, Robin M, Yakoub-Agha I, Onida F. Rovó A, et al. Among authors: mordini n. Am J Hematol. 2024 Feb;99(2):203-215. doi: 10.1002/ajh.27150. Epub 2023 Nov 27. Am J Hematol. 2024. PMID: 38009469 Free article.
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.
Bruno B, Busca A, Vallero S, Raviolo S, Mordini N, Nassi L, Cignetti A, Audisio E, Festuccia M, Corsetti A, Depaoli L, Faraci M, Micalizzi C, Corcione S, Berger M, Saglio F, Caropreso P, Mengozzi G, Squadrone V, De Rosa FG, Giaccone L. Bruno B, et al. Among authors: mordini n. Expert Rev Hematol. 2017 Jun;10(6):543-550. doi: 10.1080/17474086.2017.1326813. Epub 2017 May 24. Expert Rev Hematol. 2017. PMID: 28471695 Review.
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?
Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B. Patriarca F, et al. Among authors: mordini n. Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Expert Opin Biol Ther. 2017. PMID: 28506131 Review.
Cytogenetic abnormalities in patients with severe aplastic anemia.
Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, Bregante S, Valeriani A, Mordini N, Lamparelli T, Gualandi F, Occhini D, Bacigalupo A. Mikhailova N, et al. Among authors: mordini n. Haematologica. 1996 Sep-Oct;81(5):418-22. Haematologica. 1996. PMID: 8952154
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Giaccone L, Festuccia M, Zallio F, Sorasio R, Brunello L, Maffini E, Dellacasa C, Passera R, Iovino G, Aydin S, Boccadoro M, Vitolo U, Mordini N, Pini M, Busca A, Bruno B. Giaccone L, et al. Among authors: mordini n. Bone Marrow Transplant. 2017 Aug;52(8):1208-1211. doi: 10.1038/bmt.2017.99. Epub 2017 Jun 5. Bone Marrow Transplant. 2017. PMID: 28581461 Clinical Trial. No abstract available.
74 results